Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) and GRI Bio (NASDAQ:GRI – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.
Profitability
This table compares Seaport Therapeutics and GRI Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seaport Therapeutics | N/A | N/A | N/A |
| GRI Bio | N/A | -134.03% | -106.83% |
Valuation & Earnings
This table compares Seaport Therapeutics and GRI Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seaport Therapeutics | N/A | N/A | -$74.88 million | ($12.12) | -1.98 |
| GRI Bio | N/A | N/A | -$11.96 million | ($38.37) | -0.04 |
Seaport Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Seaport Therapeutics and GRI Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seaport Therapeutics | 2 | 3 | 5 | 0 | 2.30 |
| GRI Bio | 1 | 0 | 1 | 0 | 2.00 |
Seaport Therapeutics currently has a consensus price target of $38.40, suggesting a potential upside of 59.80%. GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,816.17%. Given GRI Bio’s higher probable upside, analysts plainly believe GRI Bio is more favorable than Seaport Therapeutics.
Institutional and Insider Ownership
34.0% of GRI Bio shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
About Seaport Therapeutics
Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
